Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

Denise A. Yardley, MD
Published: Friday, Jan 05, 2018



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

The androgen receptor is prevalent in 30% of patients with triple-negative breast cancer (TNBC). The androgen receptor is expressed in 80% to 90% in patients with HR-positive breast cancer. According to Yardley, this could be a target for the management of endocrine-positive breast cancer.

This trial had 2 cohorts. The first cohort had no prior endocrine therapy whereas the other had one prior therapy for patients with advanced disease. With a biomarker evaluation, this study predicted a group that was sensitive to enzalutamide and demonstrated progression-free survival, explains Yardley.
 


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

The androgen receptor is prevalent in 30% of patients with triple-negative breast cancer (TNBC). The androgen receptor is expressed in 80% to 90% in patients with HR-positive breast cancer. According to Yardley, this could be a target for the management of endocrine-positive breast cancer.

This trial had 2 cohorts. The first cohort had no prior endocrine therapy whereas the other had one prior therapy for patients with advanced disease. With a biomarker evaluation, this study predicted a group that was sensitive to enzalutamide and demonstrated progression-free survival, explains Yardley.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x